PMID- 36423870
OWN - NLM
STAT- MEDLINE
DCOM- 20230202
LR  - 20230213
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 353
DP  - 2023 Jan
TI  - Albumin-hitchhiking: Fostering the pharmacokinetics and anticancer therapeutics.
PG  - 166-185
LID - S0168-3659(22)00779-9 [pii]
LID - 10.1016/j.jconrel.2022.11.034 [doi]
AB  - Nanotherapeutics demonstrate poor accumulation in the tumor microenvironment due 
      to poor extravasation and penetration into the tumor. Therapeutics such as 
      oligonucleotides, peptides and other biologicals suffer from low systemic 
      half-life and rapid degradation. Albumin-hitchhiking has emerged as an effective 
      strategy to enhance tumor-specific accumulation of various therapeutics. 
      Hitchhiking on serum albumin (SA) have shown to improve biological half-life of 
      various therapeutics including nanocarriers (NCs), biologics, oligonucleotides, 
      vaccines, etc. In addition, passive and active accumulation of SA-riding 
      therapeutics in the tumor, site-specific drug release, and SA-mediated endosomal 
      escape have improved the potential of various anticancer modalities such as 
      chemo-, immune-, vaccine, and gene therapies. In this review, we have discussed 
      the advantages of employing SA-hitchhiking in anticancer therapies. In addition, 
      vaccine strategies employing inherent lymph-nodes accumulating property of 
      albumin have been discussed. We have presented a clinical overview of 
      SA-hitchhiked formulations along with possible bottlenecks for improved clinical 
      outcomes. We have also discussed the role of physiologically based 
      pharmacokinetics (PBPK) modelling for efficient characterization of anti-cancer 
      nanotherapeutics.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Famta, Paras
AU  - Famta P
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Hyderabad, India.
FAU - Shah, Saurabh
AU  - Shah S
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Hyderabad, India.
FAU - Jain, Naitik
AU  - Jain N
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Hyderabad, India.
FAU - Srinivasarao, Dadi A
AU  - Srinivasarao DA
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Hyderabad, India.
FAU - Murthy, Aditya
AU  - Murthy A
AD  - Department of Biopharmaceutics and Bioequivalence, Dr. Reddy's Laboratories Ltd., 
      Global Clinical Management Group, IPDO, Hyderabad, India.
FAU - Ahmed, Tausif
AU  - Ahmed T
AD  - Department of Biopharmaceutics and Bioequivalence, Dr. Reddy's Laboratories Ltd., 
      Global Clinical Management Group, IPDO, Hyderabad, India.
FAU - Vambhurkar, Ganesh
AU  - Vambhurkar G
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Hyderabad, India.
FAU - Shahrukh, Syed
AU  - Shahrukh S
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Hyderabad, India.
FAU - Singh, Shashi Bala
AU  - Singh SB
AD  - Department of Biological Sciences, National Institute of Pharmaceutical Education 
      and Research (NIPER), Hyderabad, India.
FAU - Srivastava, Saurabh
AU  - Srivastava S
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Hyderabad, India. Electronic address: saurabh@niperhyd.ac.in.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221125
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Serum Albumin)
RN  - 0 (Oligonucleotides)
SB  - IM
MH  - Humans
MH  - *Serum Albumin/chemistry
MH  - *Neoplasms/drug therapy
MH  - Drug Liberation
MH  - Oligonucleotides
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Albumin hitchhiking
OT  - Immunotherapy
OT  - Nanocarriers
OT  - Oligonucleotides
OT  - Peptide
OT  - Physiologically based pharmacokinetics
OT  - Vaccine
COIS- Declaration of Competing Interest Reported none.
EDAT- 2022/11/25 06:00
MHDA- 2023/02/03 06:00
CRDT- 2022/11/24 19:27
PHST- 2022/09/12 00:00 [received]
PHST- 2022/11/15 00:00 [revised]
PHST- 2022/11/16 00:00 [accepted]
PHST- 2022/11/25 06:00 [pubmed]
PHST- 2023/02/03 06:00 [medline]
PHST- 2022/11/24 19:27 [entrez]
AID - S0168-3659(22)00779-9 [pii]
AID - 10.1016/j.jconrel.2022.11.034 [doi]
PST - ppublish
SO  - J Control Release. 2023 Jan;353:166-185. doi: 10.1016/j.jconrel.2022.11.034. Epub 
      2022 Nov 25.